Target intelligence / Profile preview

Transcobalamin receptor (TCblR)

Target
TCblR
Molecular classification
Transporter, Receptor
01

Overview

The Transcobalamin receptor (TCblR/CD320) is a type I transmembrane glycoprotein crucial to mammalian cellular uptake of vitamin B12 (cobalamin). It specifically binds the transcobalamin–B12 complex on the cell surface and internalizes it via endocytosis, enabling delivery of this essential vitamin for DNA synthesis, methylation, red blood cell formation, and normal neurological function. TCblR expression is cell cycle regulated, with highest levels in proliferative tissues. Loss-of-function mutations or acquired defects result in B12 deficiency, with corresponding hematologic and neuropsychiatric sequelae. The transporter is also investigated as a target for B12-drug conjugate delivery, particularly in oncology, due to upregulation in some cancer cells. No direct small-molecule modulators are in clinical use, but the pathway is a focus for diagnostic and targeted drug strategies.

Other names
CD320Transcobalamin receptorTCblRCellular cobalamin transporter
02

Mechanism of action

Receptor-mediated endocytosis of the transcobalamin-cobalamin (TC-Cbl) complex; Uptake regulated via cell cycle and proliferation state (higher in rapidly dividing cells)

03

Biological functions

Vitamin B12 (cobalamin) uptakeCellular nutrient transportSupport of DNA synthesis and methylation pathways (via delivery of cobalamin for use as a cofactor)Support of red blood cell formation and neurological function (indirectly, via B12)
04

Disease associations

Megaloblastic anemiaNeurological disease (subacute combined degeneration, peripheral neuropathy)Hereditary cobalamin malabsorption syndromesOther metabolic disorders related to defective B12 uptake
05

Safety considerations

Deficiency syndromes: genetic defects/mutations in the CD320 gene lead to impaired B12 cellular uptake, resulting in severe metabolic and neurological phenotypesTargeted delivery limitations: therapies exploiting TCblR must account for expression in normal dividing cells, e.g., bone marrow or gut epithelium
06

Interacting drugs

No clinically approved small molecule drugs directly target the transcobalamin receptor. However, conjugates of cobalamin (B12) or transcobalamin are exploited for targeted delivery of drugs in preclinical models

1 more in the full profile.

07

Biomarkers

CD320 expressionSerum transcobalamin-bound cobalamin

Beyond the preview

Go deeper on Transcobalamin receptor (TCblR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcobalamin receptor (TCblR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call